TVTX•benzinga•
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $47
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 10, 2025 by benzinga